Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica (NMO) as next Development Program

Neil Warma, CEO of Opexa Therapeutics Inc.

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna® (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today disclosed that the Company has commenced development in a second indication, Neuromyelitis optica (NMO). NMO is a rare autoimmune disorder, which is designated as an Orphan disease by the U.S. Food and Drug … [more here...]

The Rare Daily: RARE Facts in Under a Minute

Screen Shot 2014-09-15 at 3.01.22 PM

[more here...]

Attended the 2014 Global Genes Summit and Gala? Share Your Story

Screen Shot 2014-09-15 at 2.07.48 PM

Each year Global Genes puts together a two day Patient Advocacy Summit and our Tribute to Champions of Hope Gala. For the Global Genes team it means … [more here...]

Photo & Video Roundup of 2014 Global Genes Summit and Gala Events

Screen Shot 2014-09-15 at 2.08.34 PM

We would like to extend a very heartfelt THANK YOU to everyone who spent the last few days with us online and in-person at the 3rd Annual RARE Patient … [more here...]

Jacob with Hyperekplexia Experience Extreme Stiffness

Screen Shot 2014-09-10 at 3.52.12 PM

A 4-year-old boy has been diagnosed with a rare, life-threatening illness that means he could literally be scared stiff at any moment, The Chronicle … [more here...]

Rare Disease Biotech Xenon Pharmaceuticals Files for $52 million IPO


Xenon Pharmaceuticals, an early-stage biotech with a gene therapy discovery platform for rare diseases, filed on Wednesday with the SEC to raise up to … [more here...]

The Heart and Smile of a Champion: Brigitte with Noonan Syndrome


For eight year old Brigitte Kaiser, the Tewksbury Youth Football program was more than just a fun thing to do after school. It was a chance for her … [more here...]